arginine has been researched along with Duncan Disease in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, X; Li, L; Lu, W; Tao, L; Wang, Y; Xiao, Y; Zhang, Y; Zhou, Y | 1 |
| DiNardo, CD; Tsai, DE | 1 |
| Chapel, H; Durandy, A; Fischer, A; Fugger, L; Gloire, G; Lambert, N; Latour, S; Lenoir, C; Lopez-Granados, E; Picard, C; Rigaud, S; Sibéril, S; Stacey, M; Stephan, JL; Synaeve, C | 1 |
| Faller, DV; Mentzer, SJ; Perrine, SP | 1 |
| André, F; Bayssas, M; Caillot, D; Canal, P; Casasnovas, RO; Chauffert, B; Fenaux, P; Genne, P; Grandjean, M; Guy, H; Mannone, L; Moreau, D; Solary, E; Wolf, JE; Wotawa, A | 1 |
2 review(s) available for arginine and Duncan Disease
| Article | Year |
|---|---|
Treatment advances in posttransplant lymphoproliferative disease.
Topics: Adoptive Transfer; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Arginine; Butyrates; Epstein-Barr Virus Infections; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; Humans; Immunologic Factors; Lymphoproliferative Disorders; Rituximab; T-Lymphocytes, Cytotoxic | 2010 |
Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
Topics: Antineoplastic Agents; Antiviral Agents; Arginine; Butyrates; Drug Therapy, Combination; Epstein-Barr Virus Infections; Ganciclovir; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Viral; Herpesvirus 4, Human; Humans; Lung Neoplasms; Lung Transplantation; Lymphoproliferative Disorders; Postoperative Complications; Tumor Cells, Cultured; Virus Latency | 2001 |
1 trial(s) available for arginine and Duncan Disease
| Article | Year |
|---|---|
Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cinchona Alkaloids; Cyclophosphamide; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Electrocardiography; Female; Heart; Humans; Leukopenia; Lymphoproliferative Disorders; Male; Middle Aged; Prednisone; Recurrence; Teniposide | 2000 |
2 other study(ies) available for arginine and Duncan Disease
| Article | Year |
|---|---|
Potential pathogenic mechanism of type 1 X-linked lymphoproliferative syndrome caused by a mutation of SH2D1A gene in an infant: A case report.
Topics: Amino Acids; Arginine; Humans; Infant; Intracellular Signaling Peptides and Proteins; Lymphoproliferative Disorders; Mutant Proteins; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Serine; Signaling Lymphocytic Activation Molecule Associated Protein; TOR Serine-Threonine Kinases | 2022 |
Human X-linked variable immunodeficiency caused by a hypomorphic mutation in XIAP in association with a rare polymorphism in CD40LG.
Topics: Adolescent; Adult; Arginine; CD40 Ligand; Child; Common Variable Immunodeficiency; Epistasis, Genetic; Family; Female; Genes, X-Linked; Glutamine; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Mutation; Pedigree; Polymorphism, Single Nucleotide; X-Linked Inhibitor of Apoptosis Protein; Young Adult | 2011 |